Proactive Investors - Run By Investors For Investors

Cellmid becomes profitable in December after achieving record quarterly sales

The company continued its sales growth trajectory while substantially reducing its debt.
Cellmid becomes profitable in December after achieving record quarterly sales
The company is well-funded with $5.4 million cash on hand

Cellmid Limited (ASX:CDY) has posted record sales for the second quarter of financial year 2019, earning $2.2 million or an 8% increase on the same period last year.

The company became profitable for the month of December 2018 with $278,000 net profit after tax received.

Sales growth continued across all of Cellmid’s divisions, with the USA recording the highest growth rate while Japan remains the largest contributor in terms of sales revenue.

Cellmid continued preparation of its orphan drug application during the quarter and expects to complete a filing during the March quarter.

 

Cellmid chief executive officer Maria Halasz said: “Our cash position will be further boosted in quarter three financial year 2019 as our record accounts receivable arrives.

“In addition, we have repaid all of our major debt and we are now in a strong financial position to fulfil growth expectations in current and new channels.”

READ: Cellmid driving towards profitability with anti-ageing product range

The company’s cash balance at the end of the December quarter was $5.4 million, down from $9.26 million at the end of the previous quarter.

The current receivables balance is over $1.5 million which Cellmid expects to contribute to strong cash receipts in the coming March quarter.

Significant cash outflows during the quarter included the repayments of the remaining Platinum Road loan facility with interest.

READ: Cellmid expecting record sales in December quarter, shares up 15%

Part of the company’s growth strategy has been securing the supply chain for évolis activator bottles and other packaging products.

During the quarter, Cellmid placed major orders for supplies of évolis product components to rapidly fulfil orders in the growing US and Japanese distribution.

évolis is a clinically-validated portfolio of anti-ageing hair treatments

 

READ: Cellmid partners with NZ pharmacies to distribute anti-ageing products

In November last year the company’s Lyramid patent application, entitled ‘Antibody recognizing N-domain of midkine’, was granted by the US Patent Office.

Cellmid has also received a notification of intention to grant from the European Patent Office for the corresponding Lyramid patent in key European territories.

The newly-granted midkine antibody patents and allied patent families underpin Cellmid’s intellectual property position over the use of therapeutic midkine antibodies.

This includes their use in treating diseases such as cancer, chronic inflammation, surgical adhesions and functional disorders in T-regulatory cells associated with autoimmune disease.

READ: Cellmid builds IP for midkine portfolio with new patents

Cellmid is an Australian life sciences company with lead programs in multiple disease indications.

The company develops and markets novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.

Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5 globally.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use